

## References

1. Yeap BB, Grossmann M, McLachlan RI, Handelsman DJ, Wittert GA, Conway AJ, et al. *Endocrine Society of Australia position statement on male hypogonadism (part 1): assessment and indications for testosterone therapy*. Med J Aust. 2016 Aug; 205(4): 173-178.
2. Herlihy AS, McLachlan RI. *Screening for Klinefelter syndrome*. Curr Opin Endocrinol Diabetes Obes. 2015 Jun; 22(3): 224-229.
3. Sikaris K, McLachlan RI, Kazlauskas R, de Kretser D, Holden CA, Handelsman DJ. *Reproductive hormone reference intervals for healthy fertile young men: evaluation of automated platform assays*. J Clin Endocrinol Metab. 2005 Nov; 90(11): 5928-5936. Available online at: <http://press.endocrine.org/doi/pdf/10.1210/jc.2005-0962>
4. Yeap BB, Alfonso H, Chubb SA, Handelsman DJ, Hankey GJ, Norman PE, et al. *Reference ranges and determinants of testosterone, dihydrotestosterone and estradiol levels measured using liquid chromatography-tandem mass spectrometry in a population-based cohort of older men*. J Clin Endocrinol Metab. 2012 Nov; 97(11): 4030-4039. Available online at: <http://press.endocrine.org/doi/pdf/10.1210/jc.2012-2265>
5. Ly LP, Sartorius G, Hull L, Leung A, Swerdloff RS, Wang C, et al. *Accuracy of calculated free testosterone formulae in men*. Clin Endocrinol. 2010 Sep; 73(3): 382-388.
6. Liu PY, Baker HW, Jayadev V, Zacharin M, Conway AJ, Handelsman DJ. *Induction of spermatogenesis and fertility during gonadotropin treatment of gonadotropin-deficient infertile men: predictors of fertility outcome*. J Clin Endocrinol Metab. 2009 Mar; 94(3): 801-808. Available online at: <http://press.endocrine.org/doi/pdf/10.1210/jc.2008-1648>
7. Yeap BB, Grossmann M, McLachlan RI, Handelsman DJ, Wittert GA, Conway AJ, et al. *Endocrine Society of Australia position statement on male hypogonadism (part 2): treatment and therapeutic considerations*. Med J Aust. 2016 Sep; 205(5): 228-31. Available online at: [https://www.mja.com.au/system/files/issues/205\\_05/10.5694mja16.00448.pdf](https://www.mja.com.au/system/files/issues/205_05/10.5694mja16.00448.pdf)
8. Yeap BB. *Testosterone and cardiovascular disease risk*. Curr Opin Endocrinol Diabetes Obes. 2015 Jun; 22(3): 193-202.
9. Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, et al. *Adverse events associated with testosterone administration*. N Engl J Med. 2010 Jul; 363(2): 109-122. Available online at: <http://www.nejm.org/doi/pdf/10.1056/NEJMoa1000485>
10. Srinavas-Shankar U, Roberts SA, Connolly MJ, O'Connell MDL, Adams JE, Oldham JA, et al. *Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study*. J Clin Endocrinol Metab. 2010 Feb; 95(2): 639-650. Available online at: <http://press.endocrine.org/doi/10.1210/jc.2009-1251>
11. Snyder PJ, Bhasin B, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, Cauley JA, et al. *Effects of testosterone treatment in older men*. New Engl J Med. 2016 Feb; 374(7): 611-624. Available online at: <http://www.nejm.org/doi/pdf/10.1056/NEJMoa1506119>
12. Borst SE, Shuster JJ, Zou B, Ye F, Jia H, Wokhlu A, et al. *Cardiovascular risks and elevation of serum DHT vary by route of testosterone administration: a systematic review and meta-analysis*. BMC Med. 2014 Nov; 12: 211. Available online at: <http://bmcmmedicine.biomedcentral.com/articles/10.1186/s12916-014-0211-5>
13. Handelsman DJ, Yeap BB, Flicker L, Martin S, Wittert GA, Ly LP. *Age-specific population centiles for androgen status in men*. Eur J Endocrinol. 2015 Dec; 173(6): 809-817.
14. Hyde Z, Flicker L, Almeida OP, Hankey GJ, McCaul KA, Chubb SA, et al. *Low free testosterone predicts frailty in older men: the health in men study*. J Clin Endocrinol Metab. 2010 Jul; 95(7): 3165-3172.
15. Yeap BB, Alfonso H, Chubb SA, Hankey GJ, Handelsman DJ, Golledge J, et al. *In older men, higher plasma testosterone or dihydrotestosterone are independent predictors for reduced incidence of stroke but not myocardial infarction*. J Clin Endocrinol Metab. 2014 Dec; 99(12): 4565-4573. Available online at: <http://press.endocrine.org/doi/pdf/10.1210/jc.2014-2664>
16. Yeap BB, Alfonso H, Chubb SAP, Hankey GJ, Handelsman DJ, Golledge J, et al. *In older men an optimal plasma testosterone is associated with reduced all-cause mortality, and higher dihydrotestosterone with reduced ischaemic heart disease mortality, while estradiol levels do not predict mortality*. J Clin Endocrinol Metab. 2014 Jan; 99(1): E9-E18. Available online at: <http://press.endocrine.org/doi/full/10.1210/jc.2013-3272>
17. Yeap BB, Knuiman MW, Divitini ML, Hui J, Arscott GM, Handelsman DJ, et al. *Epidemiological and Mendelian randomisation studies of dihydrotestosterone and estradiol, and leucocyte telomere length in men*. J Clin Endocrinol Metab. 2016 Mar; 101(3): 1299-1306.
18. Camacho EM, Huhtaniemi IT, O'Neill TW, Finn JD, Pye SR, Lee DM, et al. *Age-associated changes in hypothalamic-pituitary-testicular function in middle-aged and older men are modified by weight change and lifestyle factors: longitudinal results from the European Male Ageing Study*. Eur J Endocrinol. 2013(3); 168: 445-455. Available online at: <http://www.eje-online.org/content/168/3/445.full.pdf>
19. Shi Z, Araujo AB, Martin S, O'Loughlin P, Wittert GA. *Longitudinal changes in testosterone over five years in community-dwelling men*. J Clin Endocrinol Metab. 2013 Aug; 98(8): 3289-3297. Available online at: <http://press.endocrine.org/doi/pdf/10.1210/jc.2012-3842>
20. Grossmann M, Hoermann R, Wittert G, Yeap BB. *Effects of testosterone treatment on glucose metabolism and symptoms in men with Type 2 diabetes and the metabolic syndrome: a systematic review and meta-analysis of randomized controlled clinical trials*. Clin Endocrinol. 2015 Sep; 83(3): 344-351.

### **Competing interests statement:**

Prof Bu Yeap was commissioned by Healthed for this article. The ideas, opinions and information presented are solely those of the author. The advertiser does not necessarily endorse or support the views expressed in this article.

Prof Bu Yeap has received speaker honoraria and conference support from Bayer, Lilly and Besins, research support from Bayer, Lilly and Lawley Pharmaceuticals, and has participated in Advisory Boards for Lilly and Besins.

Prof Yeap is a Principal Investigator in the study “T4DM: A 2-year, multi-centre double-blind, randomised, placebo-controlled trial to determine in men with total testosterone  $\leq 14$ nmol/L the efficacy of testosterone treatment together with a lifestyle program in comparison to a lifestyle program alone, to normalise glucose tolerance in those with newly diagnosed type 2 diabetes or prevent progression to type 2 diabetes in those with pre-diabetes.” (ACTRN12612000287831, NHMRC Project Grant 1030123).